New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

How would you manage relapsed DLBCL in a patient who received second line CD19 CART treatment?

Community PollStarted

What is your preferred treatment for a fit patient with relapsed DLBCL patient who received prior 2nd line CD19 CAR-T treatment?

96 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Hematology · University of Minnesota
Answered on

With commercial CD19 CAR-T therapy moving into earlier lines of therapy, post-CAR-T relapses are now more common. There are still many options depending on what first-line/bridging therapy was given, CD19/20/30 expression, and patient preferences. I always get a biopsy if feasible to confirm relapse...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Medical Oncology · Riverside Methodist Hospitals/OhioHealth
Answered on

Since data suggests that at least 50% of relapses after CD19 CAR-T are related to loss of CD19 antigen, I would avoid using any CD19 targeting antibody (Loncastuximab tesirine or tafasitamab). I would also avoid using cytotoxic chemotherapy because the vast majority of such patients have chemorefrac...

Join for free or sign in to see the full answer

Mednet Member
Medical Oncology · Department of Medicine at NYU Grossman School of Medicine
Answered on

There are many currently FDA-approved treatments for relapsed and refractory diffuse large B-cell lymphoma. Many of these treatments target specific markers on the surface of the lymphoma cells, so where possible, I try to biopsy patients following CAR T relapse. Typically, if the marker CD20 is pre...

Join for free or sign in to see the full answer